Mechanism of action of clinically approved adjuvants
- 28 February 2009
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Immunology
- Vol. 21 (1), 23-29
- https://doi.org/10.1016/j.coi.2009.01.004
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Receptor-Independent, Direct Membrane Binding Leads to Cell-Surface Lipid Sorting and Syk Kinase Activation in Dendritic CellsImmunity, 2008
- Molecular and cellular signatures of human vaccine adjuvantsProceedings of the National Academy of Sciences of the United States of America, 2008
- The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated IL‐1β secretion but dispensable for adjuvant activityEuropean Journal of Immunology, 2008
- The NALP3 inflammasome is involved in the innate immune response to amyloid-βNature Immunology, 2008
- Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilizationNature Immunology, 2008
- Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and SilicaScience, 2008
- Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cellsThe Journal of Experimental Medicine, 2008
- The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunityBlood, 2008
- Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor SignalingScience, 2006
- Molecular identification of a danger signal that alerts the immune system to dying cellsNature, 2003